MarketFriction

Welcure Drugs & Pharmaceuticals Ltd

BSE 524661 · Pharmaceuticals
₹0.21 +0.00%
BSE close2026-10-01
Market cap₹26.0 Cr.

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales00000251213006600
Expenses000002312126954050
Operating Profit-0-0-0-0-02013111-0-50
OPM %7%10%3.0%10%17%
Other Income000000020010
Interest000000000000
Depreciation000000000000
Profit before tax-0-0-0-0-020331111-50
Tax %0%0%0%0%0%0%56%0%25%25%25%0%
Net Profit-0-0-0-0-02032381-50
EPS in Rs-0.00-0.01-0.00-0.00-0.020.010.000.020.190.070.01-0.40
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales000000000025366
Expenses000000000024372
Operating Profit000-00-000-0-01-7
OPM %20%40%33%-40%0.0%-12%46%18%4.0%-1.9%
Other Income000000000021
Interest000000000000
Depreciation000000000000
Profit before tax000-00-0000-03-5
Tax %0%0%0%0%0%0%0%0%0%22%0%
Net Profit000-00-0000-02-5
EPS in Rs0.000.010.00-0.000.00-0.000.000.000.01-0.010.02-0.04
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth127%390%%1389%
Compounded Profit Growth%%%-353%
Stock Price CAGR0%-24%-16%-60%
Return on Equity-2%-2%-2%-6%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital12121212121212121313112124
Reserves-12-12-12-12-12-12-12-12-12-12-10-27
Borrowings00000000001230
Other Liabilities000000000041413
Total Liabilities0000000021267510
Fixed Assets000000000000
CWIP000000000000
Investments000000000001
Other Assets0000000011267509
Total Assets0000000021267510
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity0-00-00-0000-0-2222
Cash from Investing Activity0000000000-0-1
Cash from Financing Activity00000000-0-02220
Net Cash Flow0-00-00-000-0000
Free Cash Flow0-00-00-0000-0-2222
CFO/OP100%-125%67%50%100%67%100%-79%57%-22,890%-25%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days00000000282213
Inventory Days2,554162
Days Payable52226
Cash Conversion Cycle000000002,784150
Working Capital Days-876368173460002,092-56
ROCE %120%-67%0%-40%133%25%10%-13%3%-3%
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Public100.00%100.00%99.99%100.00%100.00%100.00%100.00%99.98%99.99%99.99%100.00%100.00%
No. of Shareholders29,25129,59329,95731,53031,04530,21830,60532,36637,29876,95487,28887,977

Fundamentals

Market Cap₹ 26.0 Cr.
Current Price₹ 0.21
Book Value₹ 0.78
ROCE-3.40 %
ROE-5.50 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)1389%
Compounded Profit Growth (TTM)-353%
Standalone figures.
Valuation
Market capRs 26 Cr
Enterprise valueRs 25 Cr
Price to book0.27x
Price to sales0.07x
EV / sales0.07x
Price to cash flow14.91x
Earnings yield-65.47%
P/E, 3-year average4.30x
P/B, 3-year average0.22x
P/E, 5-year average23.14x
P/B, 5-year average3.53x
Profitability
Operating margin (excl. other income)-1.90%
Operating margin (incl. other income)-1.50%
EBITDA margin-1.62%
Pre-tax margin-1.62%
Net profit margin-4.65%
ROE-5.50%
ROCE-3.40%
ROA-1.41%
ROE, 3-year average-4.40%
ROCE, 3-year average-4.49%
ROA, 3-year average-3.84%
ROE, 5-year average4.84%
ROCE, 5-year average4.79%
ROA, 5-year average5.17%
ROIC (approx.)-6.15%
Other income / net worth1.50%
Growth
Sales growth (latest year)1388.96%
Profit growth (latest year)-353.00%
Sales CAGR, 5 years389.55%
Profit growth QoQ-4759.81%
Profit growth YoY (latest quarter)-2062.99%
Per share
EPS (TTM)Rs -0.14
EPS (latest quarter)Rs -0.40
EPS, 3-year averageRs 0.03
EPS, 5-year averageRs 0.04
Book value per shareRs 0.79
Sales per shareRs 2.96
Cash flow per shareRs 0.01
Free cash flow per shareRs 0.02
Efficiency
Asset turnover0.72x
Fixed asset turnover36554.00x
Inventory turnover2.25x
Inventory days162 days
Debtor days213 days
Debtors turnover1.71x
Creditor days226 days
Cash conversion cycle150 days
Working capital days-56 days
Leverage
Cash and bankRs 1 Cr
Net debtRs -1 Cr
Owners' fund to total sources19.02%
Cash flow
Cash from Operating Activity (latest year)Rs 2 Cr
Cash from Investing Activity (latest year)Rs -1 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs 2 Cr
Sales to cash flow210.08x
Statement figures
Net sales (TTM)Rs 366 Cr
Net sales (latest year)Rs 366 Cr
Operating profit excl. other income (latest year)Rs -7 Cr
Operating profit (latest quarter)Rs -50 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs -6 Cr
PBDT (TTM)Rs -6 Cr
Profit before tax (TTM)Rs -6 Cr
Net profit (TTM)Rs -17 Cr
Net profit (latest year)Rs -5 Cr
Net profit (latest quarter)Rs -50 Cr
Depreciation (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 322 Cr
Total expenditure (latest year)Rs 372 Cr
Total income (latest year)Rs 367 Cr
Share capitalRs 124 Cr
ReservesRs -27 Cr
Shareholders' fundsRs 97 Cr
Total assetsRs 510 Cr
Net blockRs 0 Cr
InvestmentsRs 1 Cr
ReceivablesRs 213 Cr
InventoryRs 144 Cr
Other liabilitiesRs 413 Cr
Shares outstanding (crore)123.57
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 0.27 is the lowest in 3.4 years (median 28.45).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
Period524661Nifty 50Difference
1 week+0.0%-2.8% +2.8 pts
1 month+5.0%-6.8% +11.8 pts
3 months-16.0%-7.6% -8.4 pts
3 years-40.0%+14.2% -54.2 pts
5 years-73.4%+27.9% -101.3 pts

Red flags

F-score 5 of 8
explainShare dilution Share count up -0% in a year, 729% in three
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Mar 2026
Sales ₹0 Cr -100.0% vs Mar 2025. Net loss ₹50 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Welcure Drugs & Pharmaceuticals Ltd?

Welcure Drugs & Pharmaceuticals Ltd (524661) has a market capitalisation of Rs 26.0 Cr. at the 2026-10-01 close.

What were Welcure Drugs & Pharmaceuticals Ltd's latest quarterly results?

In the Mar 2026 quarter, Welcure Drugs & Pharmaceuticals Ltd sales was Rs 0 Cr (-100.0% vs Mar 2025) with a net loss of Rs 50 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03